Eliane Piaggio

Eliane Piaggio is an Inserm Research Director and Team Leader of the Translational Immunotherapy team at the Institut Curie Research Center (Unit U932 - Immunity and Cancer). Her work focuses on immunotherapy strategies targeting regulatory T lymphocytes in cancer, infectious diseases, and autoimmunity.

• Studied lymph nodes draining human tumors to identify functional T cell responses
• Developed IL-2 variants for tumor-specific Treg inhibition
• Explored neoantigen responses in breast, head/neck, and melanoma cancers

Key research areas include tumor microenvironment analysis, biomarker discovery, and personalized immunotherapy development. Her team has established a tumor-draining lymph node biobank and employs advanced technologies like single-cell transcriptomics, CRISPR editing, and mass spectrometry immunopeptidomics.

Notable achievement: 2022 Ruban Rose Avenir prize recipient for predictive biomarker research in triple-negative breast cancer. Her projects aim to optimize anti-tumor immune responses through translational approaches in rhabdoid cancers and neoantigen vaccination studies.